ID   LB39-MEL
AC   CVCL_F240
SY   LB39
DR   Wikidata; Q54902065
RX   PubMed=10661410;
RX   PubMed=12747757;
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   Characteristics: Established via a mouse xenograft.
CC   HLA typing: A*02,24; B*07,51; C*w01,w07 (PubMed=12747757).
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   41Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 9
//
RX   PubMed=10661410; DOI=10.1016/S1074-7613(00)80163-6;
RA   Morel S., Levy F., Burlet-Schiltz O., Brasseur F., Probst-Kepper M.,
RA   Peitrequin A.-L., Monsarrat B., Van Velthoven R., Cerottini J.-C.,
RA   Boon T., Gairin J.-E., van den Eynde B.J.;
RT   "Processing of some antigens by the standard proteasome but not by the
RT   immunoproteasome results in poor presentation by dendritic cells.";
RL   Immunity 12:107-117(2000).
//
RX   PubMed=12747757;
RA   Jager E., Karbach J., Gnjatic S., Jager D., Maeurer M.J., Atmaca A.,
RA   Arand M., Skipper J.C.A., Stockert E., Chen Y.-T., Old L.J., Knuth A.;
RT   "Identification of a naturally processed NY-ESO-1 peptide recognized
RT   by CD8+ T cells in the context of HLA-B51.";
RL   Cancer Immun. 2:12-12(2002).
//